ReviewLung Cancer (Auckland, N.Z.)2021
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
Orla Fitzpatrick et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it
ReviewLung Cancer (Auckland, N.Z.)2021
Orla Fitzpatrick et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.